Moderna delivers Canada’s first locally manufactured mRNA vaccines
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
The inspection concluded with zero form 483 observations
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
The lab will facilitate the development of herbal and natural-based solutions
Encouraging early detection and breaking the silence around men’s health
Subscribe To Our Newsletter & Stay Updated